Breakthrough drug combo may stop hepatitis c spread in organ transplants

This study tests whether a short course of two drugs (glecaprevir/pibrentasvir and ezetimibe) can prevent hepatitis C infection in people who receive a kidney, heart, lung, or pancreas from a hepatitis C-positive donor. About 200 participants who are hepatitis C-negative and awaiting a transplant will take the drugs right after surgery. The goal is to see if this approach stops the virus from taking hold, while keeping the organ and patient healthy for at least a year.